Following the acquisition of rights to sotagliflozin (Inpefa®), Viatris has filed for regulatory approval in multiple international markets outside the U.S. and Europe. This signals a focused effort to expand the geographic reach of its new innovative products and establish a commercial footprint in new territories.
Filing excerpt
Viatris obtained the rights to sotagliflozin for all markets outside of the U.S. and Europe in October 2024. The Company filed regulatory submissions in Saudi Arabia, Canada, Australia, and New Zealand.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10kmarketExpansionGet every 10-K signal for Viatris and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Viatris this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/3b0630dd-e5b8-42f2-9864-726aa05e6e82 returns this record as JSON. POST /v1/companies/enrich returns every signal for viatris.com.
{
"signal_id": "3b0630dd-e5b8-42f2-9864-726aa05e6e82",
"signal_type": "sec-10k",
"signal_subtype": "marketExpansion",
"detected_at": "2026-03-03T06:02:41.098+00:00",
"company": {
"name": "Viatris",
"domain": "viatris.com"
},
"data": {
"detail": "Following the acquisition of rights to sotagliflozin (Inpefa®), Viatris has filed for regulatory approval in multiple international markets outside the U.S. and Europe. This signals a focused effort to expand the geographic reach of its new innovative products and establish a commercial footprint in new territories.",
"metrics": {
"timeframe": "current_year"
},
"summary": "Viatris targets global expansion with new drug filings in Canada, Australia, NZ, and Saudi Arabia.",
"excerpts": "Viatris obtained the rights to sotagliflozin for all markets outside of the U.S. and Europe in October 2024. The Company filed regulatory submissions in Saudi Arabia, Canada, Australia, and New Zealand.",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/vtrs-20251231.htm",
"filing_date": "2026-02-26",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Scaling infrastructure needed",
"signal_category": "market",
"regions_mentioned": [
"Saudi Arabia",
"Canada",
"Australia",
"New Zealand",
"U.S.",
"Europe"
]
}
}
curl https://signals.autobound.ai/v1/signals/3b0630dd-e5b8-42f2-9864-726aa05e6e82 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"viatris.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.